Results 141 to 150 of about 29,596 (259)
Orexin and Alzheimer’s Disease
, 2016 Alzheimer's disease (AD) is the most frequent age-related dementia. It prevalently causes cognitive decline, although it is frequently associated with secondary behavioral disturbances. AD neurodegeneration characteristically produces a remarkable destruction of the sleep-wake cycle, with diurnal napping, nighttime arousals, sleep fragmentation, and ...
openaire +3 more sources
Journal of Sleep Research, Volume 35, Issue 2, April 2026.ABSTRACT Daridorexant, a dual orexin receptor antagonist, is approved for the treatment of insomnia disorder in adults. Approximately 30%–35% of patients with insomnia disorder also have obstructive sleep apnoea (OSA) of any severity. It is unclear whether sleep medications provide safe and effective treatment for insomnia in these patients.
Christopher J. Lettieri +8 more
wiley +1 more source
Management of Insomnia Complaints by Non‐Sleep Specialist Physicians: A French DELPHI Consensus
Journal of Sleep Research, Volume 35, Issue 2, April 2026.ABSTRACT Insomnia is the most prevalent sleep disorder and a major public health concern, affecting chronically up to 19% of the adult population in France. Despite its significant impact on quality of life, mental health, and cardiometabolic disease, insomnia disorder remains underdiagnosed and inadequately managed.
Pierre‐Alexis Geoffroy +6 more
wiley +1 more source
Nicotine reduces adenosine release in the lateral hypothalamus : a possible mechanism of its addiction [abstract] [PDF]
, 2010 Nicotine (tobacco) addiction is a serious health issue and a leading cause of death. However, the mechanism of nicotine addiction is not fully understood.
deRoode, David +3 more
core
2026 Alzheimer's disease facts and figures
Alzheimer's &Dementia, Volume 22, Issue 4, April 2026.Abstract This article describes the public health impact of Alzheimer's disease (AD), including prevalence and incidence, mortality and morbidity, use and costs of care, and the ramifications of AD for family caregivers, the dementia workforce, and society.
wiley +1 more source
Age at Onset and Delays in Diagnosis of Central Disorders of Hypersomnolence Over the Past 30 Years
Journal of Sleep Research, Volume 35, Issue 2, April 2026.ABSTRACT Patients with narcolepsy type 1 (NT1), type 2 (NT2), idiopathic hypersomnia (IH) usually suffer from symptoms for years, even decades, before being diagnosed. We aimed to assess age at onset, age at diagnosis and changes in the diagnostic delays of these patients from 1990 to 2020 in a single centre.
Zhongxing Zhang +4 more
wiley +1 more source
Antistress effects of Kampo medicine "Yokukansan" via regulation of orexin secretion
Neuropsychiatric Disease and Treatment, 2017 Haruto Katahira,1 Masataka Sunagawa,1 Daishi Watanabe,1,2 Yasuaki Kanada,1,3 Ayami Katayama,1 Risa Yamauchi,1 Masashi Takashima,4 Shintaro Ishikawa,1 Tadashi Hisamitsu1 1Department of Physiology, 2Department of Neurology, School of Medicine, Showa ...
Katahira H +8 more
doaj
Journal of Sleep Research, Volume 35, Issue 2, April 2026.ABSTRACT The 2019 coronavirus (COVID‐19) pandemic and associated lockdowns significantly disrupted healthcare systems, including access to pharmacological treatments such as sleep medication. This study investigated the number of first‐time dispensed hypnotic drugs during the first COVID‐19 lockdown in the Netherlands, using data from the Dutch ...
Dana M. Dijkgraaf +5 more
wiley +1 more source
Physiological significance of autocrine orexinergic signaling in extra‐hypothalamic tissues
Physiological Reports, Volume 14, Issue 8, April 2026.Mechanisms of autocrine orexinergic effects in extra‐hypothalamic tissues. Abstract Orexin‐A and orexin‐B, originally discovered as hypothalamic neuropeptides, have been detected in extra‐hypothalamic tissues together with their receptors (OX1R and OX2R) since the early 2000s.
Jean Claude Hakizimana +2 more
wiley +1 more source